Clinical Trial Update: Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis

View source ↗

Summary

Clinical trial update investigating meningeal inflammation on 7T MRI as a biomarker to measure and predict ocrelizumab response in multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Multiple Sclerosis | Status: COMPLETED | Results posted: 2024-02-05